Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
In this episode, 2 experts discuss how immunotherapy has reshaped the treatment landscape of acute lymphoblastic leukemia (ALL), highlighting advances in bispecific antibodies, CAR T-cell therapies, and MRD-guided strategies in both frontline and relapsed/refractory settings. They also explore evolving decisions around toxicity, treatment sequencing, transplant, and the promise of more effective, less burdensome approaches that may further improve long-term outcomes.
Decera Clinical Education Oncology Podcast · Ibrahim Aldoss MD, Bijal Shah MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including:
- CD19-directed CAR T-cell therapies
- Next-generation CD19 bispecific antibodies
- The evolving role of allogeneic transplant
Presenters:
Ibrahim Aldoss, MD
Associate Professor
Division of Leukemia
Department of Hematology/HCT
City of Hope National Medical Center
Duarte, California
Bijal Shah, MD, MS
Senior Member, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
Link to full program:
https://bit.ly/4cRjiUi
Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.